Drug Sponsors

Report: 2015 broke R&D records

Monday, May 23, 2016

The Biotechnology Innovation Organization (BIO) has released a new report, “Emerging Therapeutic Company Investment and Deal Trends,” highlighting 10 years (2006-2015) of biotechnology funding and deal making across five areas: venture capital, IPOs, follow-on public offerings, licensing, and acquisitions. The report also offers clinical pipeline snapshots to provide context on the degree of industry partnering and the contribution of emerging companies.

[Read More]

Neuralstem plans reorganization

Friday, May 20, 2016

Neuralstem, a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, announced a corporate reorganization to further align the company’s resources on advancing the NSI-189 neurogenic small molecule program, currently in a phase II clinical trial for the treatment of major depressive disorder, and to continue to pursue collaborations for the NSI-566 stem cell therapy program that will expedite clinical development.

[Read More]

Novartis cuts pharmaceutical division in half

Friday, May 20, 2016

Novartis has announced changes to focus its Pharmaceuticals Division by creating two business units reporting to the CEO: Novartis Pharmaceuticals and Novartis Oncology. These business units will form the Innovative Medicines Division at Novartis. The leader of each business will join the Executive Committee of Novartis (ECN) effective July 1, 2016. Paul Hudson will be appointed CEO, Novartis Pharmaceuticals, and Bruno Strigini will become CEO, Novartis Oncology. Both will report directly to Joseph Jimenez, CEO of Novartis. With these changes, David Epstein, currently Division Head and CEO, Novartis Pharmaceuticals, has decided to leave Novartis. 

[Read More]

Pfizer to acquire Anacor for $5.2B

Monday, May 16, 2016

Pfizer and Anacor Pharmaceuticals have entered into a definitive merger agreement under which Pfizer will acquire Anacor for $99.25 per Anacor share, in cash, for a total transaction value, net of cash, of approximately $5.2 billion, which assumes the conversion of Anacor’s outstanding convertible notes. The Boards of Directors of both companies have unanimously approved the transaction. Anacor’s flagship asset, crisaborole, a differentiated non-steroidal topical PDE4 inhibitor with anti-inflammatory properties, is currently under review by the FDA for the treatment of mild-to-moderate atopic dermatitis, commonly referred to as eczema.

[Read More]

Alizé Pharma II acquired by Jazz Pharmaceuticals

Monday, May 16, 2016

A subsidiary of Jazz Pharmaceuticals has acquired 100% of the shares of Alizé Pharma II. This all-cash transaction closed in March 2016. The deal is valued at up to €18 million ($20.4 million), including an upfront payment of €8 million and potential payments of up to €10 million related to regulatory milestones. The transaction did not involve the transfer of any employees from the Alizé Pharma group to Jazz Pharmaceuticals.

[Read More]

Mylan to acquire Renaissance’s Specialty and Generics Business for $1B

Monday, May 16, 2016

Mylan has announced an agreement to acquire the non-sterile, topicals-focused specialty and generics business of Renaissance Acquisition Holdings for $950 million in cash at closing, plus additional contingent payments of up to $50 million, subject to customary adjustments. The transaction is expected to be immediately accretive to Mylan’s adjusted diluted earnings per share upon closing.

[Read More]

PureTech, Siddhartha Mukherjee launch Vor BioPharma

Wednesday, May 11, 2016

PureTech Health has launched Vor BioPharma, an immuno-oncology company dedicated to developing a new class of targeted cell therapies. The company, which is advancing a novel approach to chimeric antigen receptor (CAR) T-cell therapy, has licensed its core technology from the lab of Vor scientific co-founder, Siddhartha Mukherjee, M.D., Ph.D., assistant professor of Medicine at Columbia University and Pulitzer Prize-winning author of The Emperor of All Maladies: A Biography of Cancer.

[Read More]